Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: AUPH IRNT AXSM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Monday, 13 June 2022 09:40 AM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 13, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?prid=28453&wire=1
Lead Plaintiff Deadline: June 14, 2022
Class Period: May 7, 2021 - February 25, 2022

Allegations against AUPH include that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ironnet, Inc. (NYSE:IRNT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ironnet-inc-loss-submission-form?prid=28453&wire=1
Lead Plaintiff Deadline: June 21, 2022
Class Period: September 15, 2021 - December 15, 2021

Allegations against IRNT include that: (i) the Company had materially overstated its business and financial prospects; (ii) the Company was unable to predict the timing of significant customer opportunities which constituted a substantial portion of its publicly- issued FY 2022 financial guidance; (iii) the Company had not established effective disclosure controls and procedures to reasonably ensure its public disclosures were timely, accurate, complete, and not otherwise misleading; and (iv) as a result, the Company's public statements were materially false, misleading, and/or lacked any reasonable basis in fact at all relevant times.

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?prid=28453&wire=1
Lead Plaintiff Deadline: July 12, 2022
Class Period: December 30, 2019 - April 22, 2022

Allegations against AXSM include that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

The Law Offices of Vincent Wong, Monday, June 13, 2022, Press release picture

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: